NASDAQ: DHDefinitive Healthcare Corp Stock
$7.06+0.02 (+0.28%)
Updated Apr 19, 2024
DH Price
$7.06
Fair Value Price
$13.81
Market Cap
$1.11B
52 Week Low
$5.53
52 Week High
$12.46
P/E
-3.94x
P/B
1.29x
P/S
4.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$251.42M
Earnings
-$202.39M
Gross Margin
81.1%
Operating Margin
-81.83%
Profit Margin
-80.5%
Debt to Equity
0.73
Operating Cash Flow
$41M
Beta
1.6
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DH Overview
Definitive Healthcare Corp. offers business development and marketing support to help its customers optimize product development, go-to-market planning, and sales and marketing execution. Its platform offers 16 modules covering sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. Definitive Healthcare was founded in 2011 and is headquartered in Framingham, MA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DH ($7.06) is undervalued by 48.88% relative to our estimate of its Fair Value price of $13.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DH ($7.06) is significantly undervalued by 48.88% relative to our estimate of its Fair Value price of $13.81 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
DH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DH due diligence checks available for Premium users.
Be the first to know about important DH news, forecast changes, insider trades & much more!
DH News
Valuation
DH fair value
Fair Value of DH stock based on Discounted Cash Flow (DCF)
Price
$7.06
Fair Value
$13.81
Undervalued by
48.88%
DH ($7.06) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DH ($7.06) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.94x
Industry
74.39x
Market
40.51x
DH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.29x
Industry
3.35x
DH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DH's financial health
Profit margin
Revenue
$65.9M
Net Income
-$10.2M
Profit Margin
-15.5%
DH's Earnings (EBIT) of -$205.74M... subscribe to Premium to read more.
Interest Coverage Financials
DH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8B
Liabilities
$626.7M
Debt to equity
0.73
DH's short-term assets ($393.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DH's long-term liabilities ($456.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.7M
Investing
$54.4M
Financing
-$6.1M
DH's operating cash flow ($41.19M)... subscribe to Premium to read more.
Debt Coverage Financials
DH vs Health Information Service Stocks
Definitive Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.